Metropolis Healthcare Limited
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 10.3% YoY
Concerns1
- Operating margin declining for 3 consecutive years (26.0% β 24.0% β 22.0%)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.22 K Cr | β | βΉ125.00 Cr | β | β | 10.0% | 10.3% | 7.8% |
| Mar 2024 | βΉ1.10 K Cr | β | βΉ116.00 Cr | β | β | 11.3% | 3.5% | -16.5% |
| Mar 2023 | βΉ1.07 K Cr | β | βΉ139.00 Cr | β | β | 14.9% | -7.9% | -30.5% |
| Mar 2022 | βΉ1.16 K Cr | β | βΉ200.00 Cr | β | β | 23.8% | 41.8% | 1.0% |
| Mar 2021 | βΉ816.00 Cr | β | βΉ198.00 Cr | β | β | 27.9% | 22.7% | 76.8% |
| Mar 2020 | βΉ665.00 Cr | β | βΉ112.00 Cr | β | β | 21.9% | 14.5% | 10.9% |
| Mar 2019 | βΉ581.00 Cr | β | βΉ101.00 Cr | β | β | 24.3% | 19.8% | 5.2% |
| Mar 2018 | βΉ485.00 Cr | β | βΉ96.00 Cr | β | β | 26.4% | 19.8% | 9.1% |
| Mar 2017 | βΉ405.00 Cr | β | βΉ88.00 Cr | β | β | 32.8% | 16.0% | 15.8% |
| Mar 2016 | βΉ349.00 Cr | β | βΉ76.00 Cr | β | β | 31.3% | 37.4% | 76.7% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,288 |
| Total Expenses | 1,002 |
| EBIT / Operating Profit | 286 |
| OPM % | 22% |
| Other Income | 16 |
| Finance Costs | 17 |
| Depreciation & Amortisation | 110 |
| Profit Before Tax | 175 |
| Tax % | - |
| Net Profit / PAT | 133 |
| EPS (βΉ) | 25.81 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Metropolis Healthcare Limitedthis co. | βΉ9.88 K Cr | βΉ1.22 K Cr | 74.00 | 7.45 | 36.45 | 10.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |